International Guideline Harmonization Group
  • Home
  • About IGHG
    • Members
      • Core group
      • Guideline panels
        • Breast cancer
        • Cardiomyopathy
        • Premature ovarian insufficiency
        • Male gonadotoxicity
        • Thyroid cancer
        • Ototoxicty
        • Obstetric care
        • Central nervous system neoplasms
        • Fatigue, mental health and psychosocial problems
        • Fertility preservation
        • Hypothalamic-pituitary dysfunction
        • Coronary artery disease
        • Metabolic syndrome
        • Pulmonary dysfunction
        • Bone mineral density
        • Hepatic toxicity
        • Nephrotoxicity
        • Neurocognitive problems
        • Colorectal cancer
        • Splenic dysfunction
        • Dexrazoxane cardioprotection
        • Growth hormone treatment
        • COVID-19 Statement
        • Thyroid dysfunction
    • Collaborators
    • Funding sources
    • Methods
      • Process
      • Grading system
      • Topic selection
      • Publication
      • Handbook
  • Guidelines
    • Topics
      • Breast cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Cardiomyopathy
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Premature ovarian insufficiency
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Male gonadotoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Thyroid cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Ototoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Obstetric care
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Central nervous system neoplasms
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fatigue
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Psychosocial problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Mental health problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Coronary artery disease
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fertility preservation
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publications
        • Guideline panel
      • Bone mineral density
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hepatic toxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hypothalamic-pituitary dysfunction
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Metabolic syndrome
        • Guideline panel
      • Nephrotoxicity
        • Guideline panel
      • Colorectal cancer
        • Guideline panel
      • Neurocognitive problems
        • Guideline panel
      • Pulmonary dysfunction
        • Guideline panel
      • Splenic dysfunction
        • Guideline panel
      • Dexrazoxane cardioprotection
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Growth hormone treatment
      • Thyroid dysfunction
        • Guideline panel
      • COVID-19 Statement
  • Patient education
  • News
  • Meetings
  • Contact

News

Home News

News archive

  • March 2023
  • November 2022
  • May 2022
  • March 2021
  • October 2020
  • September 2020
  • April 2020
  • February 2019
  • January 2017
  • August 2016
  • July 2016
  • April 2015
  • September 2014
  • October 2013
  • February 15, 2019

    Update handbook guideline development

    The update of the Handbook for Guideline Development is now available.

    Read more
  • February 15, 2019

    Ototoxicity surveillance recommendations published

    The ototoxicity surveillance recommendations have been published in The Lancet Oncology 2019;20:e29-e41.

    Read more
  • January 18, 2017

    IGHG-PCSF meeting Copenhagen 2016

    On 21 September 2016 the IGHG and PCSF group had a guideline meeting. See meetings for the presentation slides. Please send an email to info@ighg.org for the password.

    Read more
1234567
  • Contact
  • Disclaimer

© International Guideline Harmonization Group